Bridging the Gap in FSGS: From Interpreting Proteinuria to Emerging Therapies for Enhancing Patient Outcomes and Quality of Life

This curriculum addresses persistent gaps in the management of focal segmental glomerulosclerosis (FSGS) for adult and pediatric nephrologists. In the absence of FDA-approved therapies specifically indicated for FSGS, the activities review emerging therapeutic approaches and the most current clinical evidence supporting their use. Faculty discuss the interpretation of proteinuria reduction thresholds and their relationship to long-term kidney outcomes, highlighting how treatment response may inform prognosis and clinical decision-making. The curriculum also examines the impact of FSGS on patient quality of life and emphasizes the role of patient-reported outcomes (PROs) in comprehensive disease assessment. Standardized approaches to monitoring disease progression beyond traditional measures are explored, with attention to integrating both clinical and PRO data into routine practice. By strengthening clinicians’ knowledge and interpretive skills, this initiative supports evidence-based management strategies and preparedness for potential future FSGS-targeted therapies.